Leading the Next Generation of Cell Therapy

Longeveron is committed to advancing cell therapies addressing life threatening conditions in the most vulnerable populations – children and the elderly.

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions.

Our investigational therapeutic candidate is Lomecel-B® (laromestrocel) proprietary, scalable, allogeneic cellular therapy being evaluated in multiple indications including Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (PDCM), Alzheimer’s Disease, and Age-Related Frailty.